Adjuvant Therapy - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Adjuvant Therapy

The Experts below are selected from a list of 98208 Experts worldwide ranked by ideXlab platform

Steven A Curley – 1st expert on this subject based on the ideXlab platform

  • neither neoAdjuvant nor Adjuvant Therapy increases survival after biliary tract cancer resection with wide negative margins
    Journal of Gastrointestinal Surgery, 2012
    Co-Authors: Evan S Glazer, Steven A Curley, Eddie K Abdalla, Jean Nicolas Vauthey

    Abstract:

    Background
    We investigated the role of neoAdjuvant/Adjuvant therapies on survival for resectable biliary tract cancer. We hypothesized that neoAdjuvant and Adjuvant Therapy should improve the survival probability in these patients.

Evan S Glazer – 2nd expert on this subject based on the ideXlab platform

  • neither neoAdjuvant nor Adjuvant Therapy increases survival after biliary tract cancer resection with wide negative margins
    Journal of Gastrointestinal Surgery, 2012
    Co-Authors: Evan S Glazer, Steven A Curley, Eddie K Abdalla, Jean Nicolas Vauthey

    Abstract:

    Background
    We investigated the role of neoAdjuvant/Adjuvant therapies on survival for resectable biliary tract cancer. We hypothesized that neoAdjuvant and Adjuvant Therapy should improve the survival probability in these patients.

Peter M. Ravdin – 3rd expert on this subject based on the ideXlab platform

  • Overview of Randomized Trials of Systemic Adjuvant Therapy
    Cancer treatment and research, 2008
    Co-Authors: Peter M. Ravdin

    Abstract:

    The most influential analyses of the effectiveness of systemic Adjuvant Therapy of breast cancer are the 3 overview meta-analyses performed at Oxford and published in 19881, 19922, and 19983. These meta-analyses are a collaborative effort dependent on pooling of data by trialists of nearly all the randomized clinical trials of systemic Adjuvant therapies. The major questions that were addressed by these Overview analyses were:

    1)

    Is systemic Adjuvant Therapy of breast cancer effective?

    2)

    Are there subsets of patients in whom given Adjuvant therapies are particularly effective?

    3)

    How effective is the current Adjuvant Therapy?

  • computer program to assist in making decisions about Adjuvant Therapy for women with early breast cancer
    Journal of Clinical Oncology, 2001
    Co-Authors: Peter M. Ravdin, Laura A Siminoff, Greg J Davis, Mary Beth Mercer, Joan Hewlett, Nancy Gerson, Helen L Parker

    Abstract:

    PURPOSE: The goal of the computer program Adjuvant! is to allow health professionals and their patients with early breast cancer to make more informed decisions about Adjuvant Therapy. METHODS: Actuarial analysis was used to project outcomes of patients with and without Adjuvant Therapy based on estimates of prognosis largely derived from Surveillance, Epidemiology, and End-Results data and estimates of the efficacy of Adjuvant Therapy based on the 1998 overviews of randomized trials of Adjuvant Therapy. These estimates can be refined using the Prognostic Factor Impact Calculator, which uses a Bayesian method to make adjustments based on relative risks conferred and prevalence of positive test results. RESULTS: From the entries of patient information (age, menopausal status, comorbidity estimate) and tumor staging and characteristics (tumor size, number of positive axillary nodes, estrogen receptor status), baseline prognostic estimates are made. Estimates for the efficacy of endocrine Therapy (5 years of…